(Q38571694)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Amílcar Falcão

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Maria Teresa Cruz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Bruno Neves

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

João Constantino

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

3 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

74-95

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Taking dendritic cells into medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Clinical use of dendritic cells for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Fate mapping of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Demystifying the development of dendritic cell subtypes, a little

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The origins and functions of dendritic cells and macrophages in the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Self-renewal capacity of human epidermal Langerhans cells: observations made on a composite tissue allograft.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Signalling through C-type lectin receptors: shaping immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Organization of the mouse and human DC network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Antigen crosspresentation by human plasmacytoid dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The known unknowns of antigen processing and presentation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Lipid presentation by human CD1 molecules and the diverse T cell populations that respond to them

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Intracellular mechanisms of antigen cross presentation in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Migration of dendritic cell subsets and their precursors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells and cytokines in human inflammatory and autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The role of chemokines and their receptors in dendritic cell biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells in a mature age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The role of OX40-mediated co-stimulation in T-cell activation and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

CD8 T Cell Clonal Expansion and Development of Effector Function Require Prolonged Exposure to Antigen, Costimulation, and Signal 3 Cytokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Immunological decision-making: how does the immune system decide to mount a helper T-cell response?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Effector and memory CTL differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Generation of CD8 T cell memory is regulated by IL-12.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Regulatory T cells: mechanisms of differentiation and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

CD8+ T cell efficacy in vaccination and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

CD8(+) T cells: foot soldiers of the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Interleukin-21: a double-edged sword with therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

NK cells in the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

NK cell-based immunotherapy for malignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Natural killer cells as helper cells in dendritic cell cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Inhibitory B7-family molecules in the tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

NK cells: key to success of DC-based cancer vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Mechanisms and functional significance of tumour-induced dendritic-cell defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell dysfunction in cancer: a mechanism for immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Altered maturation of peripheral blood dendritic cells in patients with breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Can the exome and the immunome converge on the design of efficient cancer vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Trial watch: Dendritic cell-based interventions for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Cancer immunotherapy with mRNA-transfected dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Emerging applications of lentiviral vectors in dendritic cell-based immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Comparison of clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell migration to peripheral lymph nodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell preparation for immunotherapeutic interventions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cells injected via different routes induce immunity in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Targeting Dendritic Cells in vivo for Cancer Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic-cell-based therapeutic cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Infection-mimicking materials to program dendritic cells in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell-based therapeutic cancer vaccines: past, present and future.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Immune checkpoint blockade: a common denominator approach to cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The roles of TGFβ in the tumour microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The blockade of immune checkpoints in cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

The future of immune checkpoint therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2015.07.008

10.1016/J.TRSL.2015.07.008

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26297944%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference